Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EPS (Weighted Average and Diluted) (2017 - 2025)

Arrowhead Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 12 years, with the latest figure at $0.22 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 115.83% year-over-year to $0.22; the TTM value through Dec 2025 reached $1.53, up 129.65%, while the annual FY2025 figure was -$0.01, 99.8% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.22 in Q4 2025 per ARWR's latest filing, up from -$0.18 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.75 in Q1 2025 to a low of -$1.39 in Q4 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.48, with a median of -$0.64 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 326.67% in 2024, then soared 369.61% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.6 in 2021, then soared by 35.0% to -$0.39 in 2022, then tumbled by 217.95% to -$1.24 in 2023, then decreased by 12.1% to -$1.39 in 2024, then surged by 115.83% to $0.22 in 2025.
  • Per Business Quant, the three most recent readings for ARWR's EPS (Weighted Average and Diluted) are $0.22 (Q4 2025), -$0.18 (Q3 2025), and -$1.26 (Q2 2025).